Date published: 2026-2-23

1-800-457-3801

SCBT Portrait Logo
Seach Input

ELMOD1 Inhibitors

ELMOD1 (ELMO Domain Containing 1) is an intriguing protein implicated in the regulation of intracellular signaling pathways that are pivotal for cell migration, cytoskeletal reorganization, and potentially autophagy. As a relatively novel entity within the realm of cellular biology, the precise functional dynamics and the breadth of its involvement in various cellular processes are subjects of ongoing research. ELMOD1 is thought to play a role in the modulation of GTPase activity, acting as a potential GTPase-activating protein (GAP) for Arf family members. This suggests a crucial role in the regulation of Arf GTPases, which are known to be involved in vesicle trafficking, actin cytoskeleton reorganization, and the maintenance of Golgi apparatus structure. The protein's exact mechanisms of action, including its specific targets within the cell and how it influences cellular behavior, remain areas ripe for exploration. Understanding the role of ELMOD1 is essential for elucidating its contribution to cellular physiology and pathology, given the importance of GTPase-mediated signaling pathways in various aspects of cell function and disease. Inhibition of ELMOD1 could involve several mechanisms, each leading to a decrease in its functional activity within the cell. Such inhibition could be achieved through direct interaction with small molecules that bind to ELMOD1, disrupting its ability to interact with Arf GTPases or interfering with its GAP activity. Another potential mechanism of inhibition could involve post-translational modifications of ELMOD1 that affect its stability, localization, or interaction with other proteins, thereby indirectly reducing its functional capacity. Additionally, gene silencing techniques, such as RNA interference, could be employed to decrease the expression levels of ELMOD1, providing another avenue for inhibition. The implications of inhibiting ELMOD1's function would likely depend on the cellular context, given its presumed role in critical signaling pathways. Understanding these mechanisms of inhibition not only sheds light on the functional importance of ELMOD1 but also contributes to the broader knowledge of cellular regulation and signaling dynamics. As research into ELMOD1 and its regulatory mechanisms progresses, it may reveal novel insights into the modulation of GTPase activities and their impact on cell biology, opening up potential areas for future investigation in understanding disease mechanisms and developing targeted interventions.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib mesylate

220127-57-1sc-202180
sc-202180A
25 mg
100 mg
$45.00
$111.00
61
(1)

Imatinib inhibits BCR-ABL tyrosine kinase by blocking its ATP-binding site, which disrupts the kinase's ability to phosphorylate substrates involved in cell growth and division, specific to CML pathogenesis.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

Gefitinib selectively inhibits EGFR tyrosine kinase by binding to its ATP-binding site, preventing autophosphorylation and subsequent activation of downstream signaling pathways involved in cell proliferation, specific to EGFR-mutated lung cancers.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Bortezomib inhibits the proteasome's chymotrypsin-like activity, leading to the accumulation of polyubiquitinated proteins, which induces cell cycle arrest and apoptosis, specific to multiple myeloma and other malignancies.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Sorafenib inhibits Raf kinases (part of the MAPK signaling pathway) and several receptor tyrosine kinases involved in angiogenesis (VEGFR and PDGFR), affecting tumor cell proliferation and blood supply, specific to renal and liver cancers.

Everolimus

159351-69-6sc-218452
sc-218452A
5 mg
50 mg
$131.00
$651.00
7
(1)

Everolimus inhibits mTOR, a key protein in a cellular signaling pathway that regulates cell growth, proliferation, and survival, specific to cancers like renal cell carcinoma where mTOR is dysregulated.

Ibrutinib

936563-96-1sc-483194
10 mg
$156.00
5
(0)

Ibrutinib irreversibly binds to Bruton's tyrosine kinase, inhibiting B-cell receptor signaling, which is critical for B-cell survival and proliferation, specific to CLL and other B-cell malignancies.

ABT-199

1257044-40-8sc-472284
sc-472284A
sc-472284B
sc-472284C
sc-472284D
1 mg
5 mg
10 mg
100 mg
3 g
$118.00
$337.00
$520.00
$832.00
$1632.00
10
(0)

ABT-199 targets and inhibits Bcl-2, a protein that prevents apoptosis in cancer cells, leading to cell death, specific to CLL and other hematologic malignancies.

Olaparib

763113-22-0sc-302017
sc-302017A
sc-302017B
250 mg
500 mg
1 g
$210.00
$305.00
$495.00
10
(1)

Olaparib inhibits PARP enzymes, which play a role in DNA repair, leading to accumulation of DNA damage and cell death, specific to BRCA-mutated cancers.

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

PD 0332991 inhibits CDK4 and CDK6, leading to cell cycle arrest at the G1 phase, specific to ER-positive, HER2-negative breast cancer.